Conference Reports for NATAP

Back

AIDS 2020 - 23rd International AIDS Conference July 6-8 2020 Virtual     2 HIV Vaccine Studies/Functional Cure & mRNA Vaccine for HIV Functional HIV Cure in Monkey with 3 Monoconal antibodies - (01/06/21)   The first long-term remission of chronic HIV-1 infection without myeloablation? (nicotinemide + maraviroc) - (08/24/20)   IAC 2020: Aging, Comorbidities, weight changes, HCV-MSM, NAFLD, Challenges-Unmet Needs of elderly PLWH - (08/24/20)   Characteristics and Predictors of Death among Hospitalized Patients with COVID-19 in Spain - (08/10/20)   Is NAFLD the same disease in HIV infected patients? - (08/10/20)   Early weight changes associated with bictegravir-based regimens compared to other integrase inhibitors following ART-initiation in ART-naïve people living with HIV - (08/10/20)   Patterns of Antiretroviral Use and Immunologic Correlates at Study Entry in the REPRIEVE Trial - (08/04/20)   Illicit Opioid Use After Changes in Opioids Prescribed for Chronic Pain Among People Living With and Without HIV - (08/01/20)   Plenary: Casualties on the road to ending HIV: Context matters in addressing HIV disparities. From the very beginning of the 40-year HIV pandemic until today, HIV disparities have remained an intractable issue. - (08/01/20)   Cabotegravir+Rilpivirine Long-Acting Injectable Treatment and Cabotegravir for PrEP study HPTN 083 at IAC 2020 - (08/01/20)   Persons Living With HIV (PLWH) in Japan on 2-Drug Regimen Reveal More Complex Patient Profiles Than That of 3-Drug Regimen Cohort - (07/27/20)   Cardiovascular and metabolic comorbidities in HIV-infected patients in Colombia: A multicenter study - (07/27/20)   Vesatolimod induces dose-dependent immune responses in HIV controllers - (07/27/20)   Changes in Body Mass Index Over Time in Persons With and Without HIV - Kaiser - (07/27/20)   COVID-19 in the Largest US HIV Cohort - (07/19/20)   To Dose-Adjust or Not to Dose-Adjust: 3TC Dose in Renal Impairment - (07/19/20)   PUTTING THE HEART BACK INTO HAART: GREATER HCP-PATIENT ENGAGEMENT IS ASSOCIATED WITH BETTER HEALTH OUTCOMES AMONG PERSONS LIVING WITH HIV (PLHIV) ON TREATMENT - (07/17/20)   Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana - (07/16/20)   Overdose Deaths Cut 10 Years Off HIV Life Expectancy: British Columbia - Mark Mascolini (07/16/20)   Characteristics of Patients Living with HIV (PLWH) and HIV Treatment Outcomes in Community Practices in Southern vs Non-Southern US Regions - (07/16/20)   FACTORS ASSOCIATED WITH RESILIENCE AMONG OLDER PEOPLE LIVING WITH HIV - (07/16/20)   HIV-1 DNA Testing in Viremic Patients Demonstrates a Greater Ability to Detect Drug Resistance Compared to Plasma Virus Testing - (07/16/20)   MODEL-BASED APPROACH OF DOSE SELECTION AND OPTIMAL PK SAMPLING OF FOSTEMSAVIR FOR PEDIATRIC PATIENTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION - (07/16/20)   COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/16/20)   Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects - (07/16/20)   ADEQUATE PLASMA LEVELS OF DOLUTEGRAVIR IN COMBINATION WITH RITONAVIR-BOOSTED DARUNAVIR: A PHARMACOKINETIC SUBGROUP-ANALYSIS OF THE DUALIS STUDY - (07/16/20)   The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH) - (07/15/20)   Global Positive Perspectives Study, Wave 2: Understanding the Unmet Needs of People Living with HIV - (07/15/20)   Cardiovascular Risk Estimation is Sub-optimal Across Two HIV Cohort - (07/15/20)   COMPARATIVE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF DOLUTEGRAVIR AND LAMIVUDINE VS 3-DRUG ANTIRETROVIRAL REGIMENS IN TREATMENT-NAIVE HIV-1 INFECTED PATIENTS AT 96 WEEKS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS - (07/15/20)   Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - Mark Mascolini (07/15/20)   COVID-19 Rate No Higher With HIV in Largest US HIV+/HIV- Cohort - Mark Mascolini (07/15/20)   The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection. - Mark Mascolini (07/15/20)   COVID-19 Disrupts PrEP Starts, Refills, HIV/STI Testing in Boston Clinic - Mark Mascolini (07/15/20)   With COVID Here, 90% of Australian MSM Have Less Sex, 40% Stop PrEP - Mark Mascolini (07/15/20)   High HCV Rate in Both Young and Older Drug Injectors--HIV Ups HCV Risk - Mark Mascolini (07/15/20)   FEASIBILITY OF IMPLEMENTING LONG-ACTING INJECTABLE ANTI-RETROVIRAL THERAPY TO TREAT HIV: A SURVEY OF HEALTH PROVIDERS FROM THE 13 COUNTRIES PARTICIPATING IN THE ATLAS-2M TRIAL - (07/15/20)   PrEP Halves New HIV Rate When Offered in Contraceptive Trial - Mark Mascolini - (07/15/20)   Doravirine Resistance Profile in Clinical Isolates and Impact of Baseline NNRTI Resistance-Associated Mutations Observed in Treatment-Naïve Participants from Phase 2 and 3 Clinical Trials - (07/15/20)   IS DTG+3TC EFFECTIVE AND SAFE IN CLINICAL PRACTICE? EVIDENCE FROM REAL WORLD DATA - (07/15/20)   COMPARISON OF VIRAL REPLICATION AT <40 C/ML FOR 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC FDC) VERSUS 3-DRUG REGIMEN (3DR) BASED ON TENOFOVIR ALAFENAMIDE (TAF) (TBR) IN THE TANGO STUDY - (07/15/20)   Is DTG+3TC effective and safe in clinical practice? Evidence from real world data - (07/15/20)   Almost Half of Older HIV+ Adults Report Poor Overall Health in 25-Country Survey - (07/15/20)   HCV Drugs for COVID-19? Three Small Studies Have Positive Hints - Mark Mascolini (07/15/20)   The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection - More Weight, Trunk Fat, Metabolic Syndrome With DTG+TAF/FTC in South African Trial - Mark Mascolini (07/15/20)   Faster virological suppression with dolutegravir versus efavirenz in pregnancy does not lower the risk of HIV mother-to-child-transmission: A meta-analysis of 5 clinical trials in 1074 pregnant women - Mark Mascolini (07/15/20)   The predicted risk of adverse pregnancy outcomes from treatment-induced obesity in the ADVANCE trial. - Dolutegravir With TAF or TDF Could Increase Adverse Pregnancy Outcomes - Mark Mascolini (07/15/20)   Racial Disparities, Communal Living in Boston COVID-19 Patients With HIV - Mark Mascolini (07/15/20)   Prevalence and Incidence of Hepatitis C Virus Infection in Men Who Have Sex With Men: A Global Systematic Review - (07/13/20)   Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: A longitudinal analysis - (07/13/20)   HCV Reinfection Rate 40% in Netherlands HIV+ MSM 5 Years After Clearance - Mark Mascolini (07/13/20)   Global HCV Burden Greater in MSM, Especially HIV+ Men: Meta-Analysis - Mark Mascolini (07/13/20)   Impact of COVID-19 on HIV preexposure prophylaxis care at a Boston community health center - (07/13/20)   Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders - (07/11/20)   Rapid Initiation of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Acute and Early Human Immunodeficiency Virus (HIV)-1 Infection: A DIAMOND Subgroup Analysis - (07/11/20)   Switching to dolutegravir plus lamivudine (DTG+3TC) is non-inferior to and as safe as continuing standard triple antiretroviral therapy (TAR) - (07/11/20)   Weight change among treatment naive women initiating dolutegravir in the ARIA study - (07/11/20)   COMPASSIONATE USE OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) AND RILPIVIRINE (RPV) FOR PATIENTS IN NEED OF PARENTERAL ANTIRETROVIRAL THERAPY - (07/11/20)   PATIENT-REPORTED OUTCOMES THROUGH WEEK 48 OF ATLAS-2M: A STUDY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE ADMINISTERED EVERY FOUR OR EIGHT WEEKS - (07/11/20)   Same COVID Mortality With/Without HIV at NY Center--More Intubations With HIV - Mark Mascolini (07/11/20)   Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Treatment-naïve (AMBER) and Virologically Suppressed (EMERALD) Patients With Neurologic and/or Psychiatric Comorbidities: Week 96 Subgroup Analysis - (07/11/20)   WEIGHT CHANGE AMONG TREATMENT-NAIVE WOMEN INITIATING DOLUTEGRAVIR IN THE ARIA STUDY - (07/10/20)   Double Drug Use, Double No-Condom Sex Boost HIV Risk With Already-Positive Partner - Mark Mascolini (07/10/20)   MSM Testing Drive Works Well in Australia-Except for One Thing - Mark Mascolini (07/10/20)   Prescribed Opioid Dose Increase Tied to Future Heroin Use in HIV+ People - Mark Mascolini - (07/10/20)   Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/10/20)   HIV Risk and Treatment Disparities Persist in US Hispanic vs White MSM - Mark Mascolini (07/10/20)   Neuropathy and Neuropathic Pain Still on Rise in HIV+, But No Clear Links to ART - Mark Mascolini (07/10/20)   Quarter Million More With HIV in US-Mostly Women-Should Get Hep A Vaccine: CDC Now Recommends HAV Vax for Everyone With HIV at Least 1 Year Old - Mark Mascolini (07/10/20)   Deep Sequencing With Unique Molecular Identifiers for Evaluation of HIV-1 Drug Resistance in the DISCOVER Pre-Exposure Prophylaxis Trial - (07/10/20)   Prevalence and Risk Factors of Preexisting NNRTI Resistance Among Suppressed PLWH in B/F/TAF Switch Studies - (07/10/20)   Clinical and sociodemographic characteristics associated with poor self-rated health across multiple domains among older adults living with HIV - (07/10/20)   Weight gain and hyperglycemia during the dolutegravir transition in Africa - (07/10/20)   Prevalence and risk factors of pre-existing NNRTI resistance among suppressed PLWH in B/F/TAF switch studies - (07/10/20)   Baseline NRTI resistance in suppressed participants did not lead to viral blips on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF through week 48 in study 380-4030 - (07/10/20)   Lenacapavir Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/10/20)   Improved metabolic parameters after switching from TAF-based 3- or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study - (07/10/20)   HPTN 083: Efficacy of Pre-exposure Prophylaxis (PrEP) containing Long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations - (07/10/20)   Projecting the burden of multimorbidity among men who have sex with men living with HIV in the US - (07/09/20)   Lenacapavir (GS-6207) Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/09/20)   Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/09/20)   Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection - (07/09/20)   Islatravir Safety Through 48 Weeks With Doravirine in Phase 2 Trial - Mark Mascolini (07/09/20)   Almost Half in US Women's Group Make PrEP Visit--But Only 10% Start PrEP - Mark Mascolini - (07/09/20)   UNDERSTANDING THE CHANGING TREATMENT CONCERNS OF OLDER PEOPLE LIVING WITH HIV (PLHIV) AND DIFFICULTIES WITH PATIENT-PROVIDER COMMUNICATION - (07/09/20)   Pooled Analysis of 4 International Trials of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Adults Aged ≥ 65 Years Demonstrating Safety and Efficacy: Week 48 Results - (07/09/20)   Doravirine, Islatravir at AIDS2020 IAC - (07/09/20)   DISCOVER Study for HIV Pre-exposure Prophylaxis: No Evidence of Risk Compensation in Participants Taking F/TDF or F/TAF for PrEP Through 96 Weeks - (07/09/20)   Weight/Body Mass Index Gains Following Initiation of Integrase Strand Transfer Inhibitor Versus Protease Inhibitor Among People Living With Human Immunodeficiency Virus in the United States - (07/09/20)   Lenacapavir (GS-6207) Sustained Delivery Formulation Supports 6-Month Dosing Interval - (07/09/20)   One Third in US Stopped PrEP During COVID Shutdown, 90% Trimmed HIV Risk - Mark Mascolini (07/09/20)   Baseline NRTI Resistance in Suppressed Participants Did Not Lead to Viral Blips on Bictegravir/Emtricitabine/Tenofovir Alafenamide B/F/TAF or Dolutegravir DTG + F/TAF Through Week 48 in Study 380-4030 - (07/08/20)   The BICSTaR prospective cohort: Real-world effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine clinical practice in people living with HIV (PLWH) - (07/08/20)   Comparative efficacy and safety of a combination therapy of dolutegravir and lamivudine vs 3-drug antiretroviral regimens in treatment-naïve HIV-1 infected patients at 96 weeks: A systematic review and network meta-analysis. - (07/08/20)   Sexually Transmitted Infections in the DISCOVER HIV PrEP Trial - (07/08/20)   IMPROVED METABOLIC PARAMETERS AFTER SWITCHING FROM TAF-BASED 3- OR 4-DRUG REGIMEN TO THE 2-DRUG REGIMEN OF DTG/3TC (DOLUTEGRAVIR/LAMIVUDINE): THE TANGO STUDY - (07/08/20)   Prevalence and Risk Factors of Preexisting NNRTI Resistance Among Suppressed PLWH in B/F/TAF Switch Studies - (07/08/20)   HPTN 083 FINAL RESULTS: Pre-exposure Prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men - (07/08/20)   Doravirine resistance profile in clinical isolates and impact of baseline NNRTI resistance-associated mutations observed in treatment-naïve participants from phase 3 clinical trials - (07/08/20)   ANALYSIS OF PROTOCOL DEFINED VIROLOGIC FAILURE THROUGH WEEK 48 FROM A PHASE 2 TRIAL (P011) OF ISLATRAVIR AND DORAVIRINE IN TREATMENT-NAÏVE ADULTS WITH HIV-1 INFECTION - (07/08/20)   ISLATRAVIR (ISL, MK-8591) SAFETY ANALYSIS THROUGH WEEK 48 FROM A PHASE 2 TRIAL IN TREATMENT NAÏVE ADULTS WITH HIV-1 INFECTION - (07/08/20)   Challenges faced by a population aging with HIV: Baseline data from the CORE healthy aging initiative (CHAI) - (07/07/20)   Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: Week 48 results - (07/07/20)   WEIGHT CHANGES AFTER SWITCH TO DORAVIRINE/LAMIVUDINE/TDF IN THE DRIVE-SHIFT TRIAL - (07/07/20)   Reducing ART to less than 3-ARV regimen linked to increased systemic inflammation - (07/07/20)   ANALYSIS OF PROTOCOL DEFINED VIROLOGIC FAILURE THROUGH WEEK 48 FROM A PHASE 2 TRIAL (P011) OF ISLATRAVIR AND DORAVIRINE IN TREATMENT-NAïVE ADULTS WITH HIV-1 INFECTION - (07/07/20)   Weight gain before and after switch from TDF to TAF - (07/07/20)   New Findings on Gilead's Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults (and pre-existing resistance) - (07/06/20)   Early Weight Gain Up to 4.5 Kg/Year With Switch From TDF to TAF: Data Suggest Independent Effect of TAF on Weight - Mark Mascolini (07/06/20)   ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices - (07/06/20)   Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207) - (07/06/20)   Heavily Pretreated US HIV Patients Face Clinical Hurdles, Higher Death Risk - Mark Mascolini (07/06/20)   No HIV Infections in PrEP Adherers, But Only 56% Continue PrEP 5 Years - Mark Mascolini (07/06/20)   High STI Rate in IPERGAY PrEP Study, But Concentrated in Subgroup - Mark Mascolini (07/06/20)   Viral Rebound No Slower When Stopping Modern ART Combinations - Mark Mascolini (07/06/20)   People With HIV Gaining Weight 3 Times Faster Than HIV-Negatives in US - Mark Mascolini (07/06/20)   Time to HIV Diagnosis Falling in US, But Half With HIV Undiagnosed After 3 Years - Mark Mascolini (07/06/20)   Only Small Weight Gains After Trial Switch to Doravirine/3TC/TDF - Mark Mascolini (07/06/20)   ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life - (07/06/20)   Kidney Disease, Diabetes Could Jump in US MSM With HIV - But Not High Lipids - Mark Mascolini (07/06/20)   Cigarette Smoking and Substance Use Each Independently Cuts Chances of HIV Control - Mark Mascolini (07/06/20)   ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual) - PRESS RELEASE - (07/02/20)   Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual - press release - (07/02/20)   Merck Underscores Commitment to HIV with New Data Analyses to be Presented at AIDS 2020: Virtual - (06/24/20)